Fujifilm expands gene therapy analytical services with $55m lab

By Vassia Barba contact

- Last updated on GMT

(Image: Getty/undefined)
(Image: Getty/undefined)

Related tags: Fujifilm diosynth biotechnologies, Cell therapy, cell and gene therapy, Gene therapy, Process analytical technology

Fujifilm Diosynth opens a 60,000-square-feet Gene Therapy Innovation Center to support upstream, downstream and analytical development services.

The laboratory space will be added to Fujifilm Diosynth Biotechnologies (FDB) gene therapy manufacturing facility in Texas, US, and is expected to boost the company’s offering of process and analytical development services for gene therapies developers.

The establishment of the laboratory space, which will cost the company $55m (€49.65m), is part of a total investment of ¥13bn ($120m) made by Fujifilm Corporation, as part of the company’s effort to meet the growing demands of the market.

“We need to invest now, in technology, assets and people,” ​commented Martin Meeson, president and COO of FDB for the US, adding that the company is ‘very much aware’ of the gene therapy market’s ‘incredible’ growth.

The facility is expected to be operational in the fall of 2021 and will add approximately 100 jobs to the company’s College Station campus in Texas.

FDB’s 80,000-square-feet plant in Texas opened early last year​, with the company looking to tap into the booming cell and gene therapies space, and provide clinical and commercial manufacturing capabilities for developers.

Earlier this year, Meeson told us that the increase of assets has led the company to establish new partnerships, with interest continuously rising, and mentioned that, at that point, the Texas facility was ‘easily expandable’ to help the company answer such demand.

Related news

Show more

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars